Fig. 4: Attenuation of GSDME or PALS2 reduces apoptotic cell death.
From: Genetic influence on vascular smooth muscle cell apoptosis
A Western blot images showing the appearance of the GSDME N-fragment (labeled GSDME-N) and C-fragment (labeled GSDME-C) from vascular smooth muscle cells (VSMCs) incubated with either staurosporine (2.5 µM) or solvent (dimethylsulfoxide, DMSO) for 1, 2, and 4 h, respectively. B Images of GSDME immunostaining of VSMCs treated with either staurosporine (2.5 µM) or solvent (DMSO) for 8 h. Orange color indicates GSDME positive staining. C Left: Western blot images showing efficient knockdown of GSDME in VSMCs transfected with GSDME siRNA. Middle and Right: Percentages of apoptotic dead VSMCs at 4-h post-staurosporine treatment (mean ± standard deviation is shown in the column chart on the right), n = 6 donors, P values from two-tailed Wilcoxon test. D Left: Western blot images showing efficient knockdown of PALS2 in VSMCs transfected with PALS2 siRNA. Middle and Right: Percentages of apoptotic dead VSMCs at 4-h post-staurosporine treatment (mean ± standard deviation is shown in the column chart on the right), n = 7 donors, P values from a two-tailed Wilcoxon test.
